Immenstadt Im Allgau

The aim of the International Hypothermia Registry is to improve rescue, treatment and outcome of accidental hypothermia victims. The principal objectives of the International Hypothermia Registry are: * Improving the outcome of accidental hypothermic patients (survival and normal neurologic function); * This outcome is dependent on the presenting status of the patient (temperature, trauma, cardiac arrest, etc.); * The hospital treatment and rewarming method will also influence the outcome, invasive vs. non-invasive rewarming and rewarming rate. * Quality control, assessment of hypothermia cases This IHR is mainly prospective but retrospective entries are welcome. There is no data limit on retrospective cases: cases of any year can be entered.

The Phase 2 portion of this study will evaluate the efficacy and safety of MRTX849 as monotherapy and in combination with pembrolizumab. There will be 3 cohorts of patients, all of whom have KRAS G12C mutation, have advanced or metastatic NSCLC, and are candidates for first-line treatment. 2 cohorts have PD-L1 TPS score \<1% and are randomized to MRTX849 monotherapy or MRTX849 in combination with pembrolizumab. The 3rd cohort has PD-L1 TPS score of 1% or higher and is treated with MRTX849 and pembrolizumab The Phase 3 portion of the study will randomize patients with squamous or nonsquamous NSCLC with KRAS G12C mutation and TPS \>=50% in the first-line setting to adagrasib plus pembrolizumab or pembrolizumab. Primary efficacy objective is to compare efficacy between experimental and comparator arms. Secondary and exploratory objectives include evaluation of secondary efficacy endpoints, safety and tolerability, adagrasib PK, PROs, and correlative genomic biomarkers for the combination regimen in the study population. MRTX849 is an orally available small molecule inhibitor of KRAS G12C, and Pembrolizumab (KEYTRUDA®) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.